Search

Your search keyword '"Arup Dasbiswas"' showing total 2 results
Start Over Author "Arup Dasbiswas" Publisher jaypee brothers medical publishing
2 results on '"Arup Dasbiswas"'

1. Role of Iron Therapy in Heart Failure: A Consensus Statement from India

Author

H K Chopra, G S Wander, Tiny Nair, C K Ponde, Navin C Nanda, Jagat Narula, Saumitra Ray, K Venugopal, S S Iyengar, R R Kasliwal, Praveen Chandra, Sunil Prakash, Sandeep Bansal, D S Rana, Prafulla Kerkar, Arup Dasbiswas, JPS Sawhney, S Shanmungasundram, Viveka Kumar, I B Vijayalakshmi, A K Pancholia, Vinod Sharma, Aditya Kapoor, Onkar C Swami, H S Isser, Vishal Rastogi, Y K Arora, Ashok K Omar, Sunil Sathe, Rajeeve Rajput, D Prabhakar, G J Paul, Priya Jagia, Poonam Malhotra, G Suryaprakash, Vinod Mittal, Manish Jagia, A Jabir, S S Mishra, S N Routray, Ajay K Sinha, Mohan Bhargava, Kiran Mahmood, Mona Bhatia, Pramila Kalra, V K Katyal, Rohit Tandon, Rahul Grover, Abhinav Chhabra, and N R Shastry

Subjects
General Medicine
Abstract

Iron deficiency (ID) with or without anemia is frequently observed in patients with heart failure (HF). Uncorrected ID is associated with higher hospitalization and mortality in patients with acute HF (AHF) and chronic HF (CHF). Hence, in addition to chronic renal insufficiency, anemia, and diabetes, ID appears as a novel comorbidity and a treatment target of CHF. Intravenous (IV) ferric carboxymaltose (FCM) reduces the hospitalization risk due to HF worsening and improves functional capacity and quality of life (QOL) in HF patients. The current consensus document provides criteria, an expert opinion on the diagnosis of ID in HF, patient profiles for IV FCM, and correct administration and monitoring of such patients

Published
2023

2. The Power and Promise of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in Heart Failure Management: National Consensus Statement

Author

H K Chopra, G S Wander, C K Ponde, Navin C Nanda, Dinesh Khullar, K Venugopal, Saumitra Ray, Tiny Nair, D S Rana, Vijay Kher, J P S Sawhney, R R Kasliwa, A Jabir, Rabin Chakraborty, Praveen Chandra, Sandeep Bansal, Viveka Kumar, A K Pancholia, Aditya Kapoor, Sunil Prakash, Anil Saxena, Vishal Rastogi, Vinod Sharma, Y K Arora, Arup Dasbiswas, Mohan Bhargava, Aparna Jaswal, K Bhargava, Mona Bhatia, A K Omar, N N Khanna, Rajiv Passey, Dilip Bhalla, I B Vijayalakshmi, A K Bhalla, Asha Moorthy, H S Isser, S S Mishra, S N Routray, Vivek Tandon, Ajay Sinha, Manish Bansal, Praveen Jain, Ramesh Hotchandani, Dharmendra Jain, V K Katyal, Sanjiv Gulati, Rohit Tandon, Shalini Jaggi, Blessy Sehgal, Vitull Gupta, Rahul Mehrotra, N C Krishnamani, S N Pathak, M S Yadav, Rajeev Chawla, Jyotirmoy Pal, Nandini Chatterjee, Shambo S Samajdar, and N R Shastry

Subjects
General Medicine
Abstract

Heart failure (HF) is a huge global public health task due to morbidity, mortality, disturbed quality of life, and major economic burden. It is an area of active research and newer treatment strategies are evolving. Recently angiotensin receptor-neprilysin inhibitor (ARNI), a class of drugs (the first agent in this class, Sacubitril–Valsartan), reduces cardiovascular mortality and morbidity in chronic HF patients with reduced left ventricular ejection fraction (LVEF). Positive therapeutic effects have led to a decrease in cardiovascular mortality and HF hospitalizations (HFH), with a favorable safety profile, and have been documented in several clinical studies with an unquestionable survival benefit with ARNI, Sacubitril–Valsartan. This consensus statement of the Indian group of experts in cardiology, nephrology, and diabetes provides a comprehensive review of the power and promise of ARNI in HF management and an evidence-based appraisal of the use of ARNI as an essential treatment strategy for HF patients in clinical practice. Consensus in this review favors an early utility of Sacubitril–Valsartan in patients with HF with reduced EF (HFrEF), regardless of the previous therapy being given. A lower rate of hospitalizations for HF with Sacubitril–Valsartan in HF patients with preserved EF who are phenotypically heterogeneous suggests possible benefits of ARNI in patients having 40–50% of LVEF, frequent subtle systolic dysfunction, and higher hospitalization risk

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results